摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-phenoxy-3-(piperidin-4-ylamino)-propan-2-ol | 890017-18-2

中文名称
——
中文别名
——
英文名称
(S)-1-phenoxy-3-(piperidin-4-ylamino)-propan-2-ol
英文别名
(2S)-1-phenoxy-3-(piperidin-4-ylamino)propan-2-ol
(S)-1-phenoxy-3-(piperidin-4-ylamino)-propan-2-ol化学式
CAS
890017-18-2
化学式
C14H22N2O2
mdl
——
分子量
250.341
InChiKey
RSIALPCKWZBJIP-ZDUSSCGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    53.5
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    [2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetic acid(S)-1-phenoxy-3-(piperidin-4-ylamino)-propan-2-olN-羟基-7-氮杂苯并三氮唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 以57%的产率得到6-(3-chloro-4-(2-[4-((S)-2-hydroxy-3-phenoxy-propylamino)-piperidin-1-yl]-2-oxo-ethoxy)-phenyl)-4,5-dihydro-2H-pyridazin-3-one
    参考文献:
    名称:
    [EN] CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
    [FR] COMPOSES CARDIOTONIQUES DOTES D'UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LES RECEPTEURS BETA-ADRENERGIQUES ET LA PHOSPHODIESTERASE
    摘要:
    公开号:
    WO2006060122A3
  • 作为产物:
    描述:
    4-((S)-2-hydroxy-3-phenoxy-propylamino)-piperidine-1-carboxylic acid tert-butyl ester 在 盐酸甲醇 作用下, 以 1,4-二氧六环甲醇 为溶剂, 反应 4.0h, 以92%的产率得到(S)-1-phenoxy-3-(piperidin-4-ylamino)-propan-2-ol
    参考文献:
    名称:
    [EN] CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
    [FR] COMPOSES CARDIOTONIQUES DOTES D'UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LES RECEPTEURS BETA-ADRENERGIQUES ET LA PHOSPHODIESTERASE
    摘要:
    公开号:
    WO2006060122A3
点击查看最新优质反应信息

文献信息

  • Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
    申请人:Taylor Malcolm George
    公开号:US20080255134A1
    公开(公告)日:2008-10-16
    The present invention provides compounds of formula (I) possessing inhibitory activity against β adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated and for treating cardiovascular disease, stroke, epilepsy, an ophthalmic disorder or migraine.
    本发明提供了具有抑制β肾上腺素受体和磷酸二酯酶(PDE)活性的式(I)化合物,包括3型磷酸二酯酶(PDE-3)。本发明还提供了包括此类化合物的制药组合物,制备此类化合物的方法,以及使用此类化合物调节钙离子稳态,治疗涉及钙离子稳态失调的疾病、紊乱或状况,以及治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
  • METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR
    申请人:Chen Gang
    公开号:US20080262226A1
    公开(公告)日:2008-10-23
    A method is provided for making compounds comprising a beta-adrenergic inhibiting moiety and a linking moiety, the method comprising: a) reacting a compound of formula (A): (R 1 —(CH—O—CH 2 )) with at least one of NH 3 , NH 4 , NH 4 ClNH 3 and R 12′ NH 2 thereby forming a compound of formula (B): (R 1 —CH(OH)—CH 2 —NHR 12′ ); and b) reacting a compound of formula (B) with a compound of formula (C): (R 3 ═O), thereby forming a compound of formula (D): (R 1 —COH—CH 2 —N(R 3 )(R 12′ )), wherein R 1 comprises the beta-adrenergic inhibiting moiety or comprises the beta-adrenergic inhibiting moiety when bonded to —COH—CH 2 —N(R 12′ )— of formula (D); R 3 comprises the linking moiety and is bonded to the =0 of formula (C) via a carbon atom; and R 12′ is selected from hydrogen and a protecting group.
    提供了一种制备含有β-肾上腺素受体抑制基团和连接基团的化合物的方法,该方法包括:a)将式(A)的化合物:(R1-(CH-O-CH2))与NH3、NH4、NH4ClNH3和R12'NH2中的至少一种反应,从而形成式(B)的化合物:(R1-CH(OH)-CH2-NHR12');b)将式(B)的化合物与式(C)的化合物反应:(R3═O),从而形成式(D)的化合物:(R1-COH-CH2-N(R3)(R12')),其中R1包括β-肾上腺素受体抑制基团,或者在与式(D)的—COH-CH2-N(R12')—结合时包括β-肾上腺素受体抑制基团;R3包括连接基团,并通过碳原子与式(C)的=0结合;R12'选择自氢和保护基团。
  • CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
    申请人:Artesian Therapeutics, Inc.
    公开号:EP1833480A2
    公开(公告)日:2007-09-19
  • [EN] CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE<br/>[FR] COMPOSES CARDIOTONIQUES DOTES D'UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LES RECEPTEURS BETA-ADRENERGIQUES ET LA PHOSPHODIESTERASE
    申请人:ARTESIAN THERAPEUTICS INC
    公开号:WO2006060122A3
    公开(公告)日:2007-03-22
查看更多